Douglas R. Galasko, MD - Publications

Neuroscience University of California, San Diego, La Jolla, CA 

130 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Edmonds EC, McDonald CR, Marshall A, Thomas KR, Eppig J, Weigand AJ, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Early versus late MCI: Improved MCI staging using a neuropsychological approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30737119 DOI: 10.1016/j.jalz.2018.12.009  0.52
2019 Thomas KR, Eppig JS, Weigand AJ, Edmonds EC, Wong CG, Jak AJ, Delano-Wood L, Galasko DR, Salmon DP, Edland SD, Bondi MW. Artificially low mild cognitive impairment to normal reversion rate in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30610833 DOI: 10.1016/j.jalz.2018.10.008  0.52
2018 Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA. Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. Journal of Alzheimer's Disease : Jad. PMID 30412501 DOI: 10.3233/JAD-180789  0.52
2018 Edmonds EC, Weigand AJ, Thomas KR, Eppig J, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. Journal of the International Neuropsychological Society : Jins. 24: 842-853. PMID 30278855 DOI: 10.1017/S1355617718000486  0.52
2018 Sundermann EE, Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Rubin LH, Bondi MW. Sex Influences the Accuracy of Subjective Memory Complaint Reporting in Older Adults. Journal of Alzheimer's Disease : Jad. 61: 1163-1178. PMID 29332038 DOI: 10.3233/JAD-170425  0.52
2018 Edmonds EC, Ard MC, Edland SD, Galasko DR, Salmon DP, Bondi MW. Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimer's & Dementia (New York, N. Y.). 4: 11-18. PMID 29296659 DOI: 10.1016/j.trci.2017.11.001  0.52
2017 Jacobs DM, Ard MC, Salmon DP, Galasko DR, Bondi MW, Edland SD. Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimer's & Dementia (New York, N. Y.). 3: 531-535. PMID 29124111 DOI: 10.1016/j.trci.2017.08.010  0.52
2016 Adamowicz DH, Roy S, Salmon DP, Galasko DR, Hansen LA, Masliah E, Gage FH. Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and is Consistent with Spread of Pathology. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28039370 DOI: 10.1523/JNEUROSCI.3047-16.2016  0.52
2016 Edmonds EC, Delano-Wood L, Jak AJ, Galasko DR, Salmon DP, Bondi MW. "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. Journal of Alzheimer's Disease : Jad. PMID 27031477 DOI: 10.3233/JAD-150986  0.52
2015 Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 47: 231-42. PMID 26402771 DOI: 10.3233/JAD-150128  0.52
2015 Ling IF, Golde TE, Galasko DR, Koo EH. Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans. Alzheimer's Research & Therapy. 7: 55. PMID 26244059 DOI: 10.1186/s13195-015-0137-y  0.52
2015 Yang Y, Keene CD, Peskind ER, Galasko DR, Hu SC, Cudaback E, Wilson AM, Li G, Yu CE, Montine KS, Zhang J, Baird GS, Hyman BT, Montine TJ. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology. 74: 672-87. PMID 26083568 DOI: 10.1097/NEN.0000000000000207  0.52
2015 Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, Edland SD, Salmon DP, Galasko DR, Bondi MW. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. Jama Neurology. 72: 546-53. PMID 25822631 DOI: 10.1001/jamaneurol.2014.4477  0.52
2015 Tinklenberg JR, Kraemer HC, Yaffe K, O'Hara R, Ringman JM, Ashford JW, Yesavage JA, Taylor JL. Donepezil treatment in ethnically diverse patients with Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 23: 384-90. PMID 25747405 DOI: 10.1016/j.jagp.2014.09.007  0.52
2015 Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 919-27. PMID 25737166 DOI: 10.1002/mds.26170  0.52
2015 Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 45: 709-19. PMID 25613100 DOI: 10.3233/JAD-143099  0.52
2015 Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, Lin X, Bammler TK, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Molecular & Cellular Proteomics : McP. 14: 544-55. PMID 25556233 DOI: 10.1074/mcp.M114.040576  0.52
2015 Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, ... ... Galasko DR, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Jama Neurology. 72: 209-16. PMID 25531812 DOI: 10.1001/jamaneurol.2014.2157  0.52
2015 Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 394-403.e1. PMID 25022538 DOI: 10.1016/j.jalz.2013.12.025  0.52
2015 Edmonds EC, Delano-Wood L, Clark LR, Jak AJ, Nation DA, McDonald CR, Libon DJ, Au R, Galasko D, Salmon DP, Bondi MW. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 415-24. PMID 24857234 DOI: 10.1016/j.jalz.2014.03.005  0.52
2015 Galasko D. Expanding the repertoire of biomarkers for Alzheimer's disease: Targeted and non-targeted approaches Frontiers in Neurology. 6. DOI: 10.3389/fneur.2015.00256  0.52
2015 MacKin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, Mattsson N. Cerebrospinal fluid α-synuclein and lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease Journal of Alzheimer's Disease. 43: 1007-1016. DOI: 10.3233/JAD-141287  0.52
2015 Breitner JCS, Galasko D. Encouraging trends toward reduced risk of Alzheimer disease Neurology: Clinical Practice. 5: 190-192. DOI: 10.1212/CPJ.0000000000000110  0.52
2015 Salmon DP, Heindel WC, Hamilton JM, Vincent Filoteo J, Cidambi V, Hansen LA, Masliah E, Galasko D. Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease Neuropsychologia. 75: 548-555. DOI: 10.1016/j.neuropsychologia.2015.07.014  0.52
2014 Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25301682 DOI: 10.1016/j.jalz.2014.07.156  0.52
2014 Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. Journal of the International Neuropsychological Society : Jins. 20: 836-47. PMID 25156329 DOI: 10.1017/S135561771400068X  0.52
2014 Peskind ER, Li G, Shofer JB, Millard SP, Leverenz JB, Yu CE, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Influence of lifestyle modifications on age-related free radical injury to brain. Jama Neurology. 71: 1150-4. PMID 25048271 DOI: 10.1001/jamaneurol.2014.1428  0.52
2014 Pan C, Zhou Y, Dator R, Ginghina C, Zhao Y, Movius J, Peskind E, Zabetian CP, Quinn J, Galasko D, Stewart T, Shi M, Zhang J. Targeted discovery and validation of plasma biomarkers of Parkinson's disease. Journal of Proteome Research. 13: 4535-45. PMID 24853996 DOI: 10.1021/pr500421v  0.52
2014 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... Galasko D, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0  0.52
2014 Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. Jama Neurology. 71: 742-51. PMID 24756381 DOI: 10.1001/jamaneurol.2014.445  0.52
2014 Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, Lu M, Adler CH, Galasko D, Liebsack C, Skovronsky DM, Sabbagh MN. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. Bmc Neurology. 14: 79. PMID 24716655 DOI: 10.1186/1471-2377-14-79  0.52
2014 Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 82: 1536-42. PMID 24696507 DOI: 10.1212/WNL.0000000000000364  0.52
2014 Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C, Seilhean D, Shaw PJ, ... ... Galasko D, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica. 127: 407-18. PMID 24442578 DOI: 10.1007/s00401-013-1239-x  0.52
2014 Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. Bmc Neurology. 14: 12. PMID 24423155 DOI: 10.1186/1471-2377-14-12  0.52
2014 Ubhi K, Rockenstein E, Kragh C, Inglis C, Spencer B, Michael S, Mante M, Adame A, Galasko D, Masliah E. Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. The European Journal of Neuroscience. 39: 1026-41. PMID 24304186 DOI: 10.1111/ejn.12444  0.52
2014 Mitolo M, Salmon DP, Gardini S, Galasko D, Grossi E, Caffarra P. The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 39: 823-32. PMID 24284368 DOI: 10.3233/JAD-131403  0.52
2014 Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. The American Journal of Psychiatry. 171: 201-8. PMID 24170170 DOI: 10.1176/appi.ajp.2013.12121590  0.52
2014 Hamilton JM, Salmon DP, Raman R, Hansen LA, Masliah E, Peavy GM, Galasko D. Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: beyond cognition. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 171-8. PMID 23850331 DOI: 10.1016/j.jalz.2013.04.003  0.52
2013 Mattsson N, Insel P, Tosun D, Zhang J, Jack CR, Galasko D, Weiner M. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. Plos One. 8: e85443. PMID 24392009 DOI: 10.1371/journal.pone.0085443  0.52
2013 Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, Quinn JF, Galasko DR. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology. 81: 2024-7. PMID 24225352 DOI: 10.1212/01.wnl.0000436935.47657.78  0.52
2013 Olichney JM, Pak J, Salmon DP, Yang JC, Gahagan T, Nowacki R, Hansen L, Galasko D, Kutas M, Iragui-Madoz VJ. Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer's disease. Cognitive Neuroscience. 4: 143-51. PMID 24090465 DOI: 10.1080/17588928.2013.838945  0.52
2013 Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics : Official Journal of the Dna Methylation Society. 8: 1030-8. PMID 23907097 DOI: 10.4161/epi.25865  0.52
2013 Pirogovsky E, Holden HM, Jenkins C, Peavy GM, Salmon DP, Galasko DR, Gilbert PE. Temporal sequence learning in healthy aging and amnestic mild cognitive impairment. Experimental Aging Research. 39: 371-81. PMID 23875836 DOI: 10.1080/0361073X.2013.808122  0.52
2013 Galasko D, Golde TE, Scheltens P. Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? Alzheimer's Research & Therapy. 5: 26. PMID 23731836 DOI: 10.1186/alzrt180  0.52
2013 Wang LY, Murphy RR, Hanscom B, Li G, Millard SP, Petrie EC, Galasko DR, Sikkema C, Raskind MA, Wilkinson CW, Peskind ER. Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. Neurobiology of Aging. 34: 2287-92. PMID 23639207 DOI: 10.1016/j.neurobiolaging.2013.04.007  0.52
2013 Lamarre AK, Rascovsky K, Bostrom A, Toofanian P, Wilkins S, Sha SJ, Perry DC, Miller ZA, Naasan G, Laforce R, Hagen J, Takada LT, Tartaglia MC, Kang G, Galasko D, et al. Interrater reliability of the new criteria for behavioral variant frontotemporal dementia. Neurology. 80: 1973-7. PMID 23635967 DOI: 10.1212/WNL.0b013e318293e368  0.52
2013 Dombroski BA, Galasko DR, Mata IF, Zabetian CP, Craig UK, Garruto RM, Oyanagi K, Schellenberg GD. C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. Jama Neurology. 70: 742-5. PMID 23588498 DOI: 10.1001/jamaneurol.2013.1817  0.52
2013 Peavy GM, Salmon DP, Edland SD, Tam S, Hansen LA, Masliah E, Galasko D, Hamilton JM. Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and "pure" Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 509-19. PMID 23567425 DOI: 10.1016/j.jagp.2012.10.022  0.52
2013 Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, ... ... Galasko D, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 78: 256-68. PMID 23562540 DOI: 10.1016/j.neuron.2013.02.026  0.52
2013 Galasko D. The diagnostic evaluation of a patient with dementia Continuum Lifelong Learning in Neurology. 19: 397-410. PMID 23558485 DOI: 10.1212/01.CON.0000429176.37224.58  0.52
2013 Galasko D, Golde TE. Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. Alzheimer's Research & Therapy. 5: 10. PMID 23470193 DOI: 10.1186/alzrt164  0.52
2013 Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, ... ... Galasko D, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. Jama Neurology. 70: 223-8. PMID 23407718 DOI: 10.1001/jamaneurol.2013.600  0.52
2013 Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. Jama Neurology. 70: 270-1. PMID 23400724 DOI: 10.1001/jamaneurol.2013.935  0.52
2013 Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D, Hewett L, Cotman CW. Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. Archives of Gerontology and Geriatrics. 56: 96-103. PMID 22959822 DOI: 10.1016/j.archger.2012.06.016  0.52
2012 Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, ... ... Galasko D, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 79: 1944-50. PMID 23035075 DOI: 10.1212/WNL.0b013e3182735e9a  0.52
2012 Bekris LM, Millard S, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Yu CE, Peskind ER. Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 159: 874-83. PMID 22927204 DOI: 10.1002/ajmg.b.32094  0.52
2012 Pillai JA, McEvoy LK, Hagler DJ, Holland D, Dale AM, Salmon DP, Galasko D, Fennema-Notestine C. Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology. 34: 925-35. PMID 22905705 DOI: 10.1080/13803395.2012.702733  0.52
2012 Wagner SL, Tanzi RE, Mobley WC, Galasko D. Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Archives of Neurology. 69: 1255-8. PMID 22801784 DOI: 10.1001/archneurol.2012.540  0.52
2012 Galasko D, Golde T, Wilcock G. Recent Alzheimer's disease research highlights. Alzheimer's Research & Therapy. 4: 14. PMID 22594696 DOI: 10.1186/alzrt117  0.52
2012 Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiology of Aging. 33: 2229.e1-2229.e9. PMID 22572541 DOI: 10.1016/j.neurobiolaging.2012.03.013  0.52
2012 Nation DA, Delano-Wood L, Bangen KJ, Wierenga CE, Jak AJ, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 30: 595-603. PMID 22451309 DOI: 10.3233/JAD-2012-111697  0.52
2012 Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology. 69: 836-41. PMID 22431837 DOI: 10.1001/archneurol.2012.85  0.52
2012 Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Archives of Neurology. 69: 368-72. PMID 22410444 DOI: 10.1001/archneurol.2011.830  0.52
2012 Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, ... ... Galasko D, et al. Phosphorylated α-synuclein in Parkinson's disease. Science Translational Medicine. 4: 121ra20. PMID 22344688 DOI: 10.1126/scitranslmed.3002566  0.52
2012 Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E. Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody. Journal of Alzheimer's Disease : Jad. 28: 783-94. PMID 22064070 DOI: 10.3233/JAD-2011-111208  0.52
2012 Peavy GM, Jacobson MW, Salmon DP, Gamst AC, Patterson TL, Goldman S, Mills PJ, Khandrika S, Galasko D. The influence of chronic stress on dementia-related diagnostic change in older adults. Alzheimer Disease and Associated Disorders. 26: 260-6. PMID 22037597 DOI: 10.1097/WAD.0b013e3182389a9c  0.52
2012 Hamilton JM, Landy KM, Salmon DP, Hansen LA, Masliah E, Galasko D. Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 773-81. PMID 21997600 DOI: 10.1097/JGP.0b013e31823033bc  0.52
2011 Gollan TH, Salmon DP, Montoya RI, Galasko DR. Degree of bilingualism predicts age of diagnosis of Alzheimer's disease in low-education but not in highly educated Hispanics. Neuropsychologia. 49: 3826-30. PMID 22001315 DOI: 10.1016/j.neuropsychologia.2011.09.041  0.52
2011 Edland SD, Galasko DR. Fractional synthesis and clearance rates for amyloid β. Nature Medicine. 17: 1178-9; author reply. PMID 21988985 DOI: 10.1038/nm.2495  0.52
2011 Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, ... ... Galasko D, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/j.pneurobio.2011.09.005  0.52
2011 Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Després S, Aigner L, ... ... Galasko DR, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 477: 90-4. PMID 21886162 DOI: 10.1038/nature10357  0.52
2011 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, ... ... Galasko D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain : a Journal of Neurology. 134: 2456-77. PMID 21810890 DOI: 10.1093/brain/awr179  0.52
2011 Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 77: 556-63. PMID 21795660 DOI: 10.1212/WNL.0b013e318228bf11  0.52
2011 Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, ... ... Galasko D, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 386-395.e6. PMID 21784349 DOI: 10.1016/j.jalz.2011.05.2243  0.52
2011 Britschgi M, Rufibach K, Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Molecular & Cellular Proteomics : McP. 10: M111.008862. PMID 21742799 DOI: 10.1074/mcp.M111.008862  0.52
2011 Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics. 43: 699-705. PMID 21685912 DOI: 10.1038/ng.859  0.52
2011 Golde TE, Lamb BT, Galasko D. Right sizing funding for Alzheimer's disease. Alzheimer's Research & Therapy. 3: 17. PMID 21554753 DOI: 10.1186/alzrt76  0.52
2011 Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, ... ... Galasko DR, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics. 43: 436-41. PMID 21460841 DOI: 10.1038/ng.801  0.52
2011 Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. The American Journal of Pathology. 178: 1509-16. PMID 21435440 DOI: 10.1016/j.ajpath.2011.01.006  0.52
2011 Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition American Journal of Alzheimer's Disease and Other Dementias. 26: 235-239. PMID 21406427 DOI: 10.1177/1533317511402316  0.52
2011 Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology. 69: 570-80. PMID 21400565 DOI: 10.1002/ana.22311  0.52
2011 Chang YL, Bondi MW, McEvoy LK, Fennema-Notestine C, Salmon DP, Galasko D, Hagler DJ, Dale AM. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology. 76: 652-9. PMID 21321338 DOI: 10.1212/WNL.0b013e31820ce6a5  0.52
2011 Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Plos One. 6: e16032. PMID 21264269 DOI: 10.1371/journal.pone.0016032  0.52
2011 Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiology of Aging. 32: 556.e13-23. PMID 21196064 DOI: 10.1016/j.neurobiolaging.2010.10.020  0.52
2011 Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Disease and Associated Disorders. 25: 206-212. PMID 21192237 DOI: 10.1097/WAD.0b013e318204b550  0.52
2011 Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Medicine. 13: 37-43. PMID 20632131 DOI: 10.1007/s12017-010-8126-6  0.52
2011 Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiology of Aging. 32: 2113-22. PMID 20452100 DOI: 10.1016/j.neurobiolaging.2010.01.010  0.52
2010 Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Archives of Neurology. 67: 1350-6. PMID 21060011 DOI: 10.1001/archneurol.2010.279  0.52
2010 Mortimer JA, Borenstein AR, Ding D, Decarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen R, Hong Z. High normal fasting blood glucose is associated with dementia in Chinese elderly. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 440-7. PMID 21044774 DOI: 10.1016/j.jalz.2010.03.017  0.52
2010 Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 68: 903-12. PMID 21035623 DOI: 10.1016/j.biopsych.2010.08.025  0.52
2010 He J, Iosif AM, Lee DY, Martinez O, Chu S, Carmichael O, Mortimer JA, Zhao Q, Ding D, Guo Q, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen RC, et al. Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase. Archives of Neurology. 67: 1231-7. PMID 20937951 DOI: 10.1001/archneurol.2010.230  0.52
2010 Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, et al. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet. Neurology. 9: 1118-27. PMID 20934914 DOI: 10.1016/S1474-4422(10)70223-4  0.52
2010 Pedrosa H, De Sa A, Guerreiro M, Maroco J, Simoes MR, Galasko D, de Mendonca A. Functional evaluation distinguishes MCI patients from healthy elderly people--the ADCS/MCI/ADL scale. The Journal of Nutrition, Health & Aging. 14: 703-9. PMID 20922349 DOI: 10.1007/s12603-010-0102-1  0.52
2010 Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, ... ... Galasko D, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Plos Genetics. 6: e1001101. PMID 20862329 DOI: 10.1371/journal.pgen.1001101  0.52
2010 Ubhi K, Peng K, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neuroscience Letters. 485: 222-7. PMID 20849919 DOI: 10.1016/j.neulet.2010.09.016  0.52
2010 Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2682-5. PMID 20818673 DOI: 10.1002/mds.23287  0.52
2010 Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. The Febs Journal. 277: 3051-67. PMID 20573181 DOI: 10.1111/j.1742-4658.2010.07719.x  0.52
2010 Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters. 480: 78-82. PMID 20540987 DOI: 10.1016/j.neulet.2010.06.009  0.52
2010 Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport. 21: 756-60. PMID 20531237 DOI: 10.1097/WNR.0b013e32833bfb7c  0.52
2010 Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomarkers in Medicine. 4: 27-36. PMID 20383271 DOI: 10.2217/bmm.09.89  0.52
2010 Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. Plos One. 5: e9313. PMID 20174468 DOI: 10.1371/journal.pone.0009313  0.52
2010 Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain : a Journal of Neurology. 133: 713-26. PMID 20157014 DOI: 10.1093/brain/awq008  0.52
2010 Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration. 5: 2. PMID 20145736 DOI: 10.1186/1750-1326-5-2  0.52
2010 Borenstein AR, Mortimer JA, Ding Ding, Schellenberg GD, DeCarli C, Qianhua Zhao, Copenhaver C, Qihao Guo, Shugang Chu, Galasko D, Salmon DP, Qi Dai, Yougui Wu, Petersen R, Zhen Hong. Effects of apolipoprotein E-epsilon4 and -epsilon2 in amnestic mild cognitive impairment and dementia in Shanghai: SCOBHI-P. American Journal of Alzheimer's Disease and Other Dementias. 25: 233-8. PMID 20142627 DOI: 10.1177/1533317509357736  0.52
2010 Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E, Galloway NM, Feldman H, Woltjer R, Miller CA, Wood EM, Grossman M, McCluskey L, Clark CM, Neumann M, ... ... Galasko DR, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Archives of Neurology. 67: 161-70. PMID 20142524 DOI: 10.1001/archneurol.2009.328  0.52
2009 Peavy GM, Salmon DP, Jacobson MW, Hervey A, Gamst AC, Wolfson T, Patterson TL, Goldman S, Mills PJ, Khandrika S, Galasko D. Effects of chronic stress on memory decline in cognitively normal and mildly impaired older adults. The American Journal of Psychiatry. 166: 1384-91. PMID 19755573 DOI: 10.1176/appi.ajp.2009.09040461  0.52
2009 Donnelly A, Galasko D, Golde T, Mulvany F, Wilcock G. Welcome to Alzheimer's research & therapy. Alzheimer's Research & Therapy. 1: 1. PMID 19671199 DOI: 10.1186/alzrt1  0.52
2009 Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 106: 12145-50. PMID 19581601 DOI: 10.1073/pnas.0904866106  0.52
2009 Sieh W, Choi Y, Chapman NH, Craig UK, Steinbart EJ, Rothstein JH, Oyanagi K, Garruto RM, Bird TD, Galasko DR, Schellenberg GD, Wijsman EM. Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Human Molecular Genetics. 18: 3725-38. PMID 19567404 DOI: 10.1093/hmg/ddp300  0.52
2009 Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. Plos One. 4: e5424. PMID 19412541 DOI: 10.1371/journal.pone.0005424  0.52
2009 Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Archives of Neurology. 66: 448-57. PMID 19364929 DOI: 10.1001/archneurol.2009.22  0.52
2009 Filoteo JV, Salmon DP, Schiehser DM, Kane AE, Hamilton JM, Rilling LM, Lucas JA, Zizak V, Galasko DR. Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia. Journal of Clinical and Experimental Neuropsychology. 31: 823-34. PMID 19221922 DOI: 10.1080/13803390802572401  0.52
2009 Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselman H, Henkel AW, Kornhuber J, et al. Consensus paper of the WFSBP task force on biological markers of dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia | Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: Contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências Revista De Psiquiatria Clinica. 36: 1-16. DOI: 10.1590/S0101-60832009000700001  0.52
2008 Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. Journal of Alzheimer's Disease : Jad. 13: 255-66. PMID 18430993  0.52
2008 Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu IL, ... ... Galasko DR, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. The Lancet. Neurology. 7: 409-16. PMID 18396105 DOI: 10.1016/S1474-4422(08)70071-1  0.52
2007 Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Disease and Associated Disorders. 21: 292-9. PMID 18090435 DOI: 10.1097/WAD.0b013e31815d1048  0.52
2007 Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine. 13: 1359-62. PMID 17934472 DOI: 10.1038/nm1653  0.52
2007 Yang W, Woltjer RL, Sokal I, Pan C, Wang Y, Brodey M, Peskind ER, Leverenz JB, Zhang J, Perl DP, Galasko DR, Montine TJ. Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. The American Journal of Pathology. 171: 993-1002. PMID 17675576 DOI: 10.2353/ajpath.2007.070015  0.52
2007 Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL, Schellenberg GD, Galasko DR. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology. 68: 1764-71. PMID 17515538 DOI: 10.1212/01.wnl.0000262027.31623.b2  0.52
2007 Sundar PD, Yu CE, Sieh W, Steinbart E, Garruto RM, Oyanagi K, Craig UK, Bird TD, Wijsman EM, Galasko DR, Schellenberg GD. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Human Molecular Genetics. 16: 295-306. PMID 17185385 DOI: 10.1093/hmg/ddl463  0.52
2007 Galasko DR. Dementia with Lewy bodies Continuum Lifelong Learning in Neurology. 13: 69-86. DOI: 10.1212/01.CON.0000267236.07498.38  0.52
2006 Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Archives of Neurology. 63: 936-9. PMID 16831961 DOI: 10.1001/archneur.63.7.936  0.52
2004 Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology. 61: 59-66. PMID 14732621 DOI: 10.1001/archneur.61.1.59  0.52
2003 Caligiuri MP, Peavy G, Salmon DP, Galasko DR, Thal LJ. Neuromotor abnormalities and risk for psychosis in Alzheimer's disease. Neurology. 61: 954-8. PMID 14557567  0.52
2001 Caligiuri MP, Peavy G, Galasko DR. Extrapyramidal signs and cognitive abilities in Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: 907-11. PMID 11571772 DOI: 10.1002/gps.443  0.52
2000 Galasko DR, Gould RL, Abramson IS, Salmon DP. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Statistics in Medicine. 19: 1421-32. PMID 10844707 DOI: 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1421::AID-SIM434>3.0.CO;2-P  0.52
2000 Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochemical and Biophysical Research Communications. 268: 750-6. PMID 10679277 DOI: 10.1006/bbrc.2000.2222  0.52
2000 Bennett DA, Galasko DR, Knopman DS, Kuhn D. Disease-a-month: Introduction Disease-a-Month. 46: 729-780.  0.52
1996 Katzman R, Galasko DR, Saitoh T, Chen X, Pay MM, Booth A, Thomas RG. Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? Neurology. 46: 889-91. PMID 8618734  0.52
1992 Caligiuri MP, Galasko DR. Quantifying drug-induced changes in parkinsonian rigidity using an instrumental measure of activated stiffness. Clinical Neuropharmacology. 15: 1-12. PMID 1576594  0.52
Show low-probability matches.